The role of NAT2 genetic variants in anti-tuberculosis drug-induced liver injury (AT-DILI): a meta-analysis

Key Points

• The aim is to determine how NAT2 genetic variants impact the risk of liver injury from anti-tuberculosis drugs.
• Conducted a meta-analysis of existing studies on NAT2 variants and drug-induced liver injury
• Evaluated the association between NAT2 acetylator status and hepatotoxicity
• Aggregated data on different studies to assess overall risk
• NAT2 acetylator status is significantly linked to hepatotoxicity from anti-tuberculosis drugs
• Patients with certain NAT2 variants have a higher likelihood of experiencing liver injury
• Results highlight the importance of genetic testing in predicting drug side effects